Evidence map›Paper›PMID 40343217›Full record

ArticleACG case reports journal2025

A Rare Presentation of a Devastating Disease: Hepatosplenic T-Cell Lymphoma in Crohn's Disease Without Thiopurine Exposure.

Michael Chang, Michael Frohlinger, Nathan Williams, Lauren George

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in ACG case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michael ChangDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD.ORCID https://orcid.org/0000-0003-3207-746X
Michael FrohlingerDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD.
Nathan WilliamsDepartment of Pathology, University of Maryland Medical Center, North Elevators, Baltimore, MD.
Lauren GeorgeDivision of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive malignancy that has been associated with thiopurines during the treatment of inflammatory bowel disease (IBD). We present a case of a 26-year-old man with Crohn's disease on infliximab without prior thiopurine exposure who developed HSTCL. His diagnosis was confirmed through flow cytometry, fluorescence in situ hybridization, and bone marrow biopsy. This is the sixth case of HSTCL in patients with IBD without prior thiopurine exposure and highlights the need for a comprehensive risk-benefit discussion with patients on the various treatment modalities for IBD.

Indexed as

Crohn'shepatosplenic T-cell lymphomainflammatory bowel diseasethiopurinestumor necrosis factor alpha inhibitors, infliximab

Identifiers

PMID40343217
PMCPMC12061462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.